Latest News and Press Releases

Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the full year ended December 31, 2024.

Liquidia has entered into a sixth amendment to its agreement with HealthCare Royalty to provide for up to an additional $100 million of financing.

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

Liquidia's Chief Executive Officer, Dr. Roger Jeffs, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.

Liquidia Corporation (LQDA) today reported financial results for the third quarter ended September 30, 2024.

Liquidia Corporation (LQDA) to present at the Stifel 2024 Healthcare Conference in New York City on Tuesday, November 19, 2024, from 3:00 – 3:30 p.m. ET.

Liquidia Corporation (LQDA) to report its third quarter 2024 financial results on November 13, 2024, via webcast at 8:30 a.m. ET

Liquidia Corporation (NASDAQ: LQDA), to report its third quarter 2024 financial results via webcast at 8:30 a.m. ET on Friday, November 8, 2024.

U.S. Supreme Court denied United Therapeutics’ petition to appeal rulings that found all claims of U.S. Patent No. 10,716,793 (‘793 Patent) were invalidDecisions that Liquidia does not infringe any...

Liquidia and Pharmosa announced they have amended the current exclusive licensing agreement for the development and commercialization of L606.